The Food and Drug Administration approved a new oncolytic viral therapy — an engineered virus designed to attack cancer cells — for patients with advanced melanoma who have not responded to other treatments, the agency announced Aug. 6.
The approval covers patients with treatment-resistant advanced melanoma, the deadliest form of skin cancer, who have limited remaining options after failing immunotherapy and other standard treatments.
Oncolytic viral therapy represents a distinct mechanism from the checkpoint inhibitors and targeted therapies that currently dominate melanoma treatment. The engineered virus is designed to selectively infect and destroy cancer cells while stimulating the patient’s immune response against the tumor.
The drug received a priority review designation from the FDA, a status reserved for therapies that offer significant improvements over existing treatments for serious conditions. The FDA’s Oncology Center of Excellence led the review.
Advanced melanoma that has stopped responding to immunotherapy carries a poor prognosis. The approval provides a new treatment pathway for patients who have exhausted existing options.
Details on the specific manufacturer and brand name were not available in the FDA’s summary announcement. The approval adds to a growing portfolio of novel cancer therapies cleared by the agency in 2026.